Cardiovascular biomarker market could hit $7.2B by 2018

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

The global market of diagnostic biomarkers for the detection of cardiovascular disease is expected to soar steadily at a compound annual growth rate (CAGR) of 12.8 percent between 2013 and 2018.

The March report titled “Cardiac Biomarkers: Technologies and Global Markets” was developed by BCC Research and announced April 10.

According to the report, the worldwide market for cardiac biomarkers was valued around $4 billion last year, up from an estimated $3.1 billion in 2012.

The report notes a trend during this five-year period in biomarkers for heart failure, especially ST2 and galectin-3, and others for the detection of stroke, including GFAP and S100-beta.

The biomarkers driving the market were listed as B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI) and troponin T (cTnT).

Kathy Mahdoubi

Related Content

Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes

Around the web

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease. 

Cardiovascular Business
Cardiology, radiology specialists debate CCTA’s rise as a go-to imaging modality for CAD

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care.